Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Akero Therapeutics Inc (NQ: AKRO )

20.96 +1.30 (+6.64%)
Streaming Delayed Price Updated: 12:53 PM EDT, May 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Akero Therapeutics Inc

< Previous 1 2 Next >
Akero Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster Presentations on EFX at AASLD’s The Liver Meeting® 2023
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 7th Annual NASH Virtual Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Inc. (NASDAQ: AKRO) is a Stock Spotlight on 6/9
Via Investor Brand Network
Akero Therapeutics Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH
Investor webcast on Tuesday, October 10 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces Publication of the Harmony Phase 2b Trial Results in The Lancet Gastroenterology & Hepatology
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in September
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Report Results of Phase 2b SYMMETRY Study in October 2023
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Presents Analyses of Phase 2b HARMONY Study at the 2023 International Liver Congress Reinforcing and Characterizing EFX-Related Improvements in Liver Histopathology
Data show changes in non-invasive tests in EFX-treated patients were associated with improvements in NASH histopathology and highlight dose-dependent responses 
From Akero Therapeutics
Via GlobeNewswire
3 Mid Caps You Haven't Heard Of But Need To Know About
Here are three mid-cap stocks that will not have been on the radar for most readers but whose recent performance warrants closer inspection and consideration. 
Via MarketBeat
Exposures Product Safety
Akero Therapeutics’ Phase 2b SYMMETRY Cohort D Study Met Safety & Tolerability Endpoints and Showed Adding EFX to GLP-1 Therapy Significantly Improved Non-Invasive Markers of NASH-Related Disease
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Investor webcast on Monday, June 5 at 8:00 a.m. ET to present clinical data 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the Jefferies Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces Pricing of $220.0 Million Underwritten Offering of Common Stock
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial Strategy
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Completes Enrollment of Phase 2b SYMMETRY Study and Announces Expected 2023 Milestones
From Akero Therapeutics
Via GlobeNewswire
Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH
Designation based on Akero’s Phase 2b HARMONY study finding that both the 50mg and 28mg EFX doses achieved statistical significance on primary and secondary histology endpoints after 24 weeks 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at Upcoming Healthcare Conferences in November
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present Late-Breaking Oral and Poster presentations on EFX Today at AASLD’s The Liver Meeting® 2022
Phase 2b HARMONY study presentation selected for inclusion in the Best of the Liver meeting in the NASH/NAFLD category 
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics to Present at the H.C. Wainwright 6th Annual NASH Investor Conference
From Akero Therapeutics
Via GlobeNewswire
Akero Therapeutics (NASDAQ: AKRO) Squeezes Shorts After Stronger-then-Expected Results from Phase 2b HARMONY Study of EFX
Akero Therapeutics, Inc. (NASDAQ: AKRO) is engaged as a clinical-stage biotechnology company that is focused on the research and development 
Via Spotlight Growth
Akero Therapeutics Inc. (NASDAQ: AKRO) Sets New 52-Week High in Tuesday Morning Session
Via Investor Brand Network
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.